DICE Therapeutics, Inc.
DICEDelisted Aug 9, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645569
DICE Therapeutics, Inc. was delisted on Aug 9, 2023; its insiders filed their last Form 4 on Aug 9, 2023; 160 institutions reported holding it in 13F filings for Q2 2023, worth $2.12B in total; Fairfax Financial was the only superinvestor holding it.
Q2 2022 vs. Q1 2022
How the institutions holding DICE Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 76 | 2 | 80 | +6 |
| Shares | 33.4M | 46.7K | 36.4M | +3.11M (+9.3%) |
| Value | $637.5M | $894.0K | $564.6M | −$71.9M (−11.3%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held DICE Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Balyasny Asset Management LLC | 274,821 | $4.26M | 0.02% |
| Ally Bridge Group (NY) LLC | 207,290 | $3.22M | 2.93% |
| Susquehanna International Group, LLP | 35,384 | $549.0K | 0.00% |
| Ghost Tree Capital, LLC | 30,000 | $466.0K | 0.32% |
| M&T Bank Corp | 28,476 | $442.0K | 0.00% |
| Voloridge Investment Management, LLC | 25,692 | $399.0K | 0.00% |
| Alliancebernstein L.P. | 22,600 | $351.0K | 0.00% |
| Swiss National Bank | 22,500 | $349.0K | 0.00% |
| Qube Research & Technologies Ltd | 17,903 | $278.0K | 0.00% |
| State Board of Administration of Florida Retirement System | 14,080 | $219.0K | 0.00% |
| Gsa Capital Partners LLP | 13,325 | $207.0K | 0.03% |
| Voya Investment Management LLC | 10,567 | $164.0K | 0.00% |
| Credit Suisse AG | 8,857 | $138.0K | 0.00% |
| SG Americas Securities, LLC | 8,429 | $131.0K | 0.00% |
| Private Capital Group, LLC | 89 | $1.00K | 0.00% |
| Massmutual Trust Co FSB | 30 | $0 | 0.00% |
| Quantbot Technologies LP | 39 | $0 | 0.00% |
| Rockefeller Capital Management L.P. | 34 | $0 | 0.00% |
| Ronald Blue Trust, Inc. | 13 | $0 | 0.00% |
Sold out (13)
Institutions that held DICE Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Point72 Asset Management, L.P. | 398,000 | $7.61M |
| Vivo Capital, LLC | 163,136 | $3.12M |
| Board of Trustees of The Leland Stanford Junior University | 58,492 | $1.12M |
| HighVista Strategies LLC | 48,960 | $937.0K |
| Acuta Capital Partners, LLC | 37,500 | $717.0K |
| Adage Capital Partners GP, L.L.C. | 30,000 | $574.0K |
| State of Wisconsin Investment Board | 18,600 | $356.0K |
| Parkwood LLC | 12,417 | $238.0K |
| D. E. Shaw & Co., Inc. | 10,718 | $205.0K |
| Cubist Systematic Strategies, LLC | 5,035 | $96.0K |
| STRS Ohio | 3,200 | $61.0K |
| Prospera Financial Services Inc | 2,052 | $39.0K |
| UBS Group AG | 2,059 | $39.0K |
Not filed for Q2 2022 yet (2)
Institutions that held DICE Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 44,710 | $855.0K |
| Amalgamated Financial Corp. | 2,029 | $39.0K |